The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Patient adherence in COPD
Open accessAbstract
Patient adherence to treatment in chronic obstructive pulmonary disease (COPD) is essential to optimise disease management. As with other chronic diseases, poor adherence is common and results in increased rates of morbidity, healthcare expenditures, hospitalisations and possibly mortality, as well as unnecessary escalation of therapy and reduced quality of life. Examples include overuse, underuse, and alteration of schedule and doses of medication, continued smoking and lack of exercise. Adherence is affected by patients' perception of their disease, type of treatment or medication, the quality of patient provider communication and the social environment. Patients are more likely to adhere to treatment when they believe it will improve disease management or control, or anticipate serious consequences related to non-adherence. Providers play a critical role in helping patients understand the nature of the disease, potential benefits of treatment, addressing concerns regarding potential adverse effects and events, and encouraging patients to develop self-management skills. For clinicians, it is important to explore patients' beliefs and concerns about the safety and benefits of the treatment, as many patients harbour unspoken fears. Complex regimens and polytherapy also contribute to suboptimal adherence. This review addresses adherence related issues in COPD, assesses current efforts to improve adherence and highlights opportunities to improve adherence for both providers and patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies suggested that the misuse or rejection of medication or NIV can be influenced by some psychological factors such as anxiety, depression, health beliefs, and cognitive impairment (27–29); the unacknowledged recognition of the illness; and the use of different devices and medications due to comorbidities (30–32).”
From Promoting Acceptance and Adherence to Noninvasive Ventilation in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. (2022) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Murray, C. J. L., & López, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
Adherence to Long-Term Therapies: Evidence for Action
Geest, S. D., & Sabate, E. J. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,310
Global Initiative for Chronic Obstructive Lung Disease
Gerald, L. B., & Bailey, W. C. (2002) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200207000-00004 · Cited by 5,806
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Chronic Obstructive Pulmonary Disease
Flavin, K., Morkane, C. M., & Marsh, S. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108233712.025 · Cited by 2,687
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., Menezes, A. M., Sullivan, S. D., Lee, T. A., Weiss, K. B., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61377-4 · Cited by 2,364
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation
Nici, L., Donner, C., Wouters, E., Zuwallack, R., Ambrosino, N., Bourbeau, J., Carone, M., Celli, B., Engelen, M., Fahy, B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200508-1211st · Cited by 1,966
Self-citation
Flagged first, then by citations
1 of the 101 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 489
Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD
Gelb, A. F., Tashkin, D. P., Make, B. J., Zhong, X., Gil, E. G., & Caracta, C. F. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.07.001 · Cited by 43
The Importance of Inhaler Adherence to Prevent COPD Exacerbations
Jardim, J. R., & Nascimento, O. A. (2019) · Medical Sciences · doi:10.3390/medsci7040054 · Cited by 43
“The reasons for the poor adherence in the clinical settings are multifactorial and may be related to [19,20]:”
BackgroundIerodiakonou, D., Sifaki-Pistolla, D. I., Kampouraki, M., Poulorinakis, I., Papadokostakis, P., Gialamas, I., Athanasiou, P., Bempi, V., Lampraki, I., Tsiligianni, I., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01296-3 · Cited by 43
Terry, P., & Dhand, R. (2023) · Pulmonary Therapy · doi:10.1007/s41030-023-00233-z · Cited by 42
“adherence (Table 1) [22, 23], and patients with COPD experience as high as 50–80% non-adherence with prescribed inhaled therapy [22, 24].”
BackgroundPulmonary Diseases in Older Patients: Understanding and Addressing the Challenges
Joshi, P. R. (2024) · Geriatrics · doi:10.3390/geriatrics9020034 · Cited by 53
“…and support groups, addressing anxiety, depression, and coping strategies, involving family members to enhance mental resilience Regular monitoring [172] Monitoring lung function, symptoms, and medication adherence, scheduled follow-ups End-of-life planning [173] Open discussions about end-of-life…”
BackgroundExtrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
Singh, D., Nicolini, G., Bindi, E., Corradi, M., Guastalla, D., Kampschulte, J., Pierzchała, W., Sayıner, A., Szilasi, M., Terzano, C., et al. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-43 · Cited by 42
“The benefit achieved after the first dose may be important in providing patients with reassurance regarding drug effectiveness, which will likely improve medication compliance [29].”
BackgroundKim, J.-A., Lim, M. K., Kim, K.-I., Park, J., & Rhee, C. K. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0612-2 · Cited by 42
Banfi, P. I., Cappuccio, A., Latella, M., Reale, L., Muscianisi, E., & Marini, M. G. (2018) · International Journal of COPD · doi:10.2147/copd.s148685 · Cited by 44
The dose of inhaled corticosteroids in patients with COPD: when less is better
Alonso, J. L. I., & Cosío, B. G. (2018) · International Journal of COPD · doi:10.2147/copd.s175047 · Cited by 42
“increase the risk of adverse events and raise concerns about adherence to prescribed medications.(10) At the same time, some subgroups of patients with COPD, such as those with greater lung function impairment, are highly susceptible to recurrent exacerbations that increase the severity of their condition.”
Price, D. B., Lee, A. J., Sims, E. J., Kemp, L., Hillyer, E. V., Chisholm, A., von Ziegenweidt, J., & Williams, A. (2013) · Primary Care Respiratory Journal · doi:10.4104/pcrj.2013.00017 · Cited by 41
Gregoriano, C., Dieterle, T., Breitenstein, A.-L., Dürr, S., Baum, A., Giezendanner, S., Maier, S., Leuppi-Taegtmeyer, A. B., Arnet, I., Hersberger, K. E., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1219-3 · Cited by 41
The INCATM (Inhaler Compliance AssessmentTM): A comparison with established measures of adherence
Moran, C. N., Doyle, F., Sulaiman, I., Bennett, K., Greene, G., Molloy, G. J., Reilly, R. B., Costello, R. W., & Mellon, L. (2017) · Psychology and Health · doi:10.1080/08870446.2017.1290243 · Cited by 41
“The chronic, progressive and debilitating nature of COPD, alongside its high prevalence, confers significant burden on the health care system (Bourbeau & Bartlett, 2008).”
BackgroundEsposti, L. D., Buda, S., Nappi, C., Paoli, D., & Perrone, V. (2020) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s265264 · Cited by 42
The use of treatable traits to address COPD complexity and heterogeneity and to inform the care
Duszyk, K., McLoughlin, R. F., Gibson, P. G., & McDonald, V. M. (2021) · Breathe · doi:10.1183/20734735.0118-2021 · Cited by 40
“Indeed, patient adherence is one of the main contributors to suboptimal COPD management and subsequently poor clinical outcomes [43].”
BackgroundShakshuki, A., & Agu, R. U. (2017) · Pulmonary Therapy · doi:10.1007/s41030-017-0046-2 · Cited by 40
“thoroughly demonstrating inhaler technique, and overall ineffective communication between provider and patient [24, 25].”
BackgroundTen years of tiotropium: clinical impact and patient perspectives
Yohannes, A. M., Connolly, M. J., & Hanania (2013) · International Journal of COPD · doi:10.2147/copd.s28576 · Cited by 39
“It is convenient for the COPD patients’ self-management and has a potential to improve patient adherence and compliance with treatment.(11) Tiotropium bromide has been available since 2002, and is widely prescribed in over 110 countries worldwide with patient experience of over 25 million patient-years.”
Characteristics of Undertreatment in COPD in the General Population
Ingebrigtsen, T. S., Marott, J. L., Vestbo, J., Hallas, J., Nordestgaard, B. G., Dahl, M., & Lange, P. (2013) · CHEST Journal · doi:10.1378/chest.13-0453 · Cited by 39
Costello, R. W., Foster, J. M., Grigg, J., Eakin, M. N., Canonica, G. W., Yunus, F., & Ryan, D. P. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.04.002 · Cited by 39
“In older/elderly patients, the impact of nonadherence to respiratory medications includes increased rates of morbidity, health care expenditures, hospitalizations, and possibly mortality, as well as unnecessary escalation of therapy and reduced quality of life.(12,13) Although there is a substantial body of evidence o…”
BackgroundMaria, M. D., Vellone, E., Ausili, D., Alvaro, R., Mauro, S. D., Piredda, M., Marinis, M. D. D., & Matarese, M. (2018) · Journal of Advanced Nursing · doi:10.1111/jan.13834 · Cited by 36
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
Ohar, J. A., Cohen, J., Miles, M., & Donohue, J. F. (2016) · International Journal of COPD · doi:10.2147/copd.s54513 · Cited by 39
“Efficacy is a moot issue without adherence, a significant problem in COPD treatment.(81) Generally, adherence increases with a simpler dosing regimen (once daily .”
Cazzola, M., Beeh, K. M., Price, D. B., & Roche, N. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.02.007 · Cited by 37
Dhand, R., Mahler, D. A., Carlin, B. W., Hanania, N. A., Ohar, J. A., Pinto-Plata, V., Shah, T., Eubanks, D. H., & Braman, S. S. (2018) · Respiratory Care · doi:10.4187/respcare.05715 · Cited by 41
Treatment Adherence in Patients with Obstructive Pulmonary Diseases
Homętowska, H., Świątoniowska-Lonc, N., Klekowski, J., Chabowski, M., & Jankowska‐Polańska, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811573 · Cited by 37
“Data from observational studies indicate that adherence rates in patients with obstructive pulmonary diseases usually range between 10% and 40% [4] and that non-compliance is the most common cause of exacerbations, which indicate whether or not treatment is effective.”
BackgroundAsthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®
Hodder, R. (2009) · International Journal of COPD · doi:10.2147/copd.s3452 · Cited by 37
Working with the Noncompliant Patient
Kleinsinger, F. (2010) · The Permanente Journal · doi:10.7812/tpp/09-064 · Cited by 37
Wakabayashi, R., Motegi, T., Yamada, K., Ishii, T., Gemma, A., & Kida, K. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.03222.x · Cited by 35
“Alternatively, people who live with a spouse or caregiver receive support and encouragement, which can have a positive effect on adherence to COPD management.(27,36) Those living alone had poorer adherence to pulmonary Table 2.”
BackgroundBalu, S., Simko, R. J., Quimbo, R. M., & Cziraky, M. J. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903297741 · Cited by 36
Jung, K., Kil, Y., Jung, J., Park, S., Shin, D., Lee, K., Seo, E. K., & Bae, H. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.11.015 · Cited by 35
Dry Powder Inhalers: a Concise Summary of the Electronic Monitoring Devices
Mehta, P. P. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0091 · Cited by 35
Tang, J. E., Mandrusiak, A., & Russell, T. G. (2012) · International Journal of Telemedicine and Applications · doi:10.1155/2012/798791 · Cited by 35
“Although PR has been shown to be effective in managing symptoms and reducing hospital admissions, poor participation and adherence are a current problem among outpatient programs [18].”
BackgroundBelleudi, V., Martino, M. D., Cascini, S., Kirchmayer, U., Pistelli, R., Formoso, G., Fusco, D., Davoli, M., Agabiti, N., & on behalf of the OUTPUL Study Group (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4059 · Cited by 35
Barnestein‐Fonseca, P., Leiva-Fernández, J., Vidal-España, F., Ruíz, A., Prados-Torres, D., & Leiva-Fernández, F. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-6 · Cited by 34
“While a major goal of therapy is to provide symptoms relief, only the effective management of COPD has been shown to reduce the rate of exacerbations, hospitalisations and mortality and to improve health-related quality of life [3].”
BackgroundMethodManaging multimorbidity in primary care in patients with chronic respiratory conditions
Morrison, D., Agur, K., Mercer, S. W., Eiras, A., González-Montalvo, J. I., & Gruffydd‐Jones, K. (2016) · npj Primary Care Respiratory Medicine · doi:10.1038/npjpcrm.2016.43 · Cited by 34
“Nonadherence to treatments can be influenced by several factors such as the complexity of the dosing schedule, frequent changes in medication, multiple medication, side effects, the cost of drugs, difficult routes of administration, difficult-to-open containers, cognitive impairment, visual impairment, inadequate pati…”
BackgroundPossibilities of ICT-supported services in the clinical management of older adults
Vollenbroek-Hutten, M. M. R., Jansen-Kosterink, S. M., Tabak, M., Feletti, L. C., Zia, G., N’dja, A., & Hermens, H. J. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0711-6 · Cited by 35
“However, as professionals are important to help patients understand their disease, the potential benefits of treatment and prevention, and encouraging development of self-management skills [30] their attitude towards telemedicine greatly influences the perception and adherence of the patients.”
BackgroundPatient Knowledge in Chronic Obstructive Pulmonary Disease: Back to Basics
Scott, A. S., Baltzan, M., Dajczman, E., & Wolkove, N. (2011) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2011.605402 · Cited by 33
“Chronic obstructive pulmonary disease (COPD) is a disabling chronic illness that may produce a negative spiraling effect on breathing and quality of life (1,2).”
BackgroundJackson, D. S., Banerjee, S., Sirey, J. A., Pollari, C. D., Solomonov, N., Novitch, R. S., Chalfin, A., Wu, Y., & Alexopoulos, G. S. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.12.004 · Cited by 32
Siu, D. C. H., & Gafni-Lachter, L. (2024) · International Journal of COPD · doi:10.2147/copd.s426050 · Cited by 32
Vogelmeier, C. F., & Banerji, D. D. (2011) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465811406001 · Cited by 32
“Once-daily dosing has the potential to improve adherence with medication in patients with COPD [Bourbeau and Bartlett, 2008] and has been associated with higher levels of persistence [Breekveldt-Postma et al. 2007].”
BackgroundHellem, E., Bruusgaard, K. A., & Bergland, A. (2011) · Physiotherapy Theory and Practice · doi:10.3109/09593985.2011.587502 · Cited by 36
“More recently, the term concordance has been used to describe a partnership or therapeutic alliance involving patients in decision making, thereby empowering patients to play an active role in his/her disease management (Bourbeau, 2008).”
BackgroundA novel model-based approach for dose determination of glycopyrronium bromide in COPD
Arievich, H., Overend, T., Renard, D., Gibbs, M., Alagappan, V., Looby, M., & Banerji, D. D. (2012) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-12-74 · Cited by 32
“However, simplification of dosing regimens by reducing dosing frequency has been shown to improve adherence with medication [16,17] and has been linked with higher levels of persistence [4,18,19]; increased adherence is strongly associated with reduced hospitalization and healthcare utilization costs [20,21].”
BackgroundFischer, M. J., Scharloo, M., Abbink, J. J., Hul, A. J. V. ‘., van Ranst, D., Rudolphus, A., Weinman, J. A., Rabe, K. F., & Kaptein, A. A. (2010) · International Journal of Behavioral Medicine · doi:10.1007/s12529-010-9130-9 · Cited by 32
“Currently, COPD patients' concerns about treatment tend to be underrepresented in the communication between patients and healthcare providers [52].”
BackgroundPoletti, V., Pagnini, F., Banfi, P. I., & Volpato, E. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s412136 · Cited by 31
“depend on whether patients are outcome-oriented, for example, “feeling better”, or process-oriented, like being more regular with the medication use.(11)”
BackgroundYang, T., Cai, B., Cao, B., Kang, J., Wen, F., Chen, Y., Jian, W., Shang, H., & Wang, C. (2022) · Respiratory Research · doi:10.1186/s12931-022-02021-w · Cited by 32
Berlana, D., Talaverón, J. M. L., Manresa, F., & Jódar, R. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.2.146 · Cited by 31
The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Huurne, K. K.-T., Movig, K. L. L., van der Valk, P., van der Palen, J. A. M., & Brusse-Keizer, M. G. J. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1130695 · Cited by 30
Dransfield, M. T., Feldman, G., Korenblat, P. E., LaForce, C., Locantore, N., Pistolesi, M., Watkins, M. L., Crim, C. C., & Martínez, F. J. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.05.008 · Cited by 30
“Dosing frequency has been suggested to influence adherence to therapy [5], though it is not the sole factor [6].”
BackgroundGeneral practitioners’ perceptions of COPD treatment: thematic analysis of qualitative interviews
Molin, K. R., Egerod, I., Valentiner, L. S., Lange, P., & Langberg, H. (2016) · International Journal of COPD · doi:10.2147/copd.s108611 · Cited by 30
“Smoking cessation can delay further disease, and both medical treatment and physical activity can reduce symptoms.(1,3) Rehabilitation programs, with physical activity, patient education, and smoking cessation as treatment elements, have proven to be important for 1) reducing breathlessness, 2) improving exercise capa…”
A new pulmonary rehabilitation maintenance strategy through home-visiting and phone contact in COPD
Li, Y., Feng, J., Li, Y., Jia, W. P., & Qian, H. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s150679 · Cited by 30
Tal‐Singer, R., Cahn, A. P., Mehta, R. S., Preece, A., Crater, G., Kelleher, D. L., & Pouliquen, I. J. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.019 · Cited by 29
“Adherence to COPD medications is often poor and dosing frequency is a factor in patient adherence to treatment (Bourbeau and Bartlett, 2008).”
BackgroundAdherence to Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review
Świątoniowska-Lonc, N., Chabowski, M., Polański, J., Mazur, G. J., & Jankowska‐Polańska, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2019_477 · Cited by 29
Doctor-patient relationship: a resource to improve respiratory diseases management.
Santus, P., Picciolo, S., Proietto, A., Falcone, F., Mangiacavallo, A., Pellegrino, G., Sereno, F., Radovanovic, D., Blasi, F., Girbino, G., et al. (2012) · European journal of internal medicine · doi:10.1016/j.ejim.2012.04.004 · Cited by 29
“One of the difficultieswith the intervention in mild and moderate COPD is that patients might have some troubles with adherence to long-term drugs [12].”
BackgroundCharacteristics of prevalent and new COPD cases in Greece: the GOLDEN study
Mitsiki, E., Bania, E., Varounis, C., Gourgoulianis, K. I., & Alexopoulos, E. C. (2015) · International Journal of COPD · doi:10.2147/copd.s81468 · Cited by 28
“The high proportion of patients forgetting to take their medication might be due to the presence of multiple comorbidities and thus they may need to take multiple treatments, related to higher age, while complex dosing schedules and perception of limited efficacy can also cause low compliance rates.(33) Extra care sho…”
Wurst, K., Laurent, S. S., Müllerová, H., & Davis, K. J. (2014) · International Journal of COPD · doi:10.2147/copd.s58258 · Cited by 28
“recognized that adherence to pharmacotherapy in COPD is generally suboptimal.(21) The updated 2013 GOLD strategy recommends the use of SABD for bronchodilation, and consequently, an increase in the number of recorded SABD prescriptions dispensed may also indicate more symptoms and greater disease severity.”
MethodCarter, N. J. (2013) · Drugs · doi:10.1007/s40265-013-0058-7 · Cited by 28
“As is the case for many other chronic diseases [7], patient adherence to COPD therapy is often suboptimal [7– 11], and this in turn may be associated with poor clinical outcomes and increased healthcare costs [7, 12].”
BackgroundDong, H., Hao, Y., Li, D., Su, Z., Li, W., Shi, B., & Gao, P. (2020) · International Journal of COPD · doi:10.2147/copd.s270729 · Cited by 28
Ta, M., & George, J. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02133.x · Cited by 28
Hwang, J. P., Roundtree, A. K., Engebretson, J. C., & Suarez-Almazor, M. E. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1204-5 · Cited by 28
Khanna, V., Feldman, G., Spangenthal, S., Eckert, J. H., Henley, M., Patalano, F., D’Andrea, P., & LaForce, C. (2016) · International Journal of COPD · doi:10.2147/copd.s100445 · Cited by 27
“In addition, prompt symptom relief could be a key factor in patient compliance; medication that does not have an immediate effect on symptoms might reduce the chance of a patient continuing with treatment.(16) Hence, symptomatic patients could benefit more from glycopyrrolate therapy.”
Abdulsalim, S., Unnikrishnan, M. K., Manu, M. K., Alsahali, S. M., Alrasheedy, A. A., Martin, A. P., Godman, B., & Alfadl, A. A. (2019) · PharmacoEconomics - Open · doi:10.1007/s41669-019-0172-x · Cited by 27
Half a Century of Technological Advances in Pulmonary Drug Delivery: A Personal Perspective
Clark, A. R. (2022) · Frontiers in Drug Delivery · doi:10.3389/fddev.2022.871147 · Cited by 27
“However, despite these great advances, adherence and compliance remain major hurdles to effective therapy (Bourbeau and Bartlett, 2008; Restrepo et al., 2008; Vestbo et al., 2009).”
BackgroundGeßner, C., Trinkmann, F., Javan, S. B., Hövelmann, R., Bogoevska, V., Georges, G. C., Nudo, E., & Criée, C.-P. (2022) · International Journal of COPD · doi:10.2147/copd.s382405 · Cited by 27
Barnestein‐Fonseca, P., Leiva-Fernández, J., Vidal-España, F., Ruíz, A., Prados-Torres, D., & Leiva-Fernández, F. (2011) · Trials · doi:10.1186/1745-6215-12-40 · Cited by 27
“Another factor is the patient’s disease perception that leads to the discontinuation of therapy due to a lack of or excess of clinical symptoms, inconvenient or expensive medication [12].”
BackgroundLay Health Coaching to Increase Appropriate Inhaler Use in COPD: A Randomized Controlled Trial
Willard‐Grace, R., Chirinos, C., Wolf, J. S., DeVore, D., Huang, B., Hessler, D., Tsao, S., Su, G., & Thom, D. H. (2020) · The Annals of Family Medicine · doi:10.1370/afm.2461 · Cited by 26
Knox, L., Gemine, R. E., Rees, S., Bowen, S., Groom, P., Taylor, D., Bond, I. A., Rosser, W., & Lewis, K. E. (2020) · Health and Technology · doi:10.1007/s12553-020-00494-7 · Cited by 27
Volpato, E., Banfi, P., & Pagnini, F. (2022) · Psychosomatic Medicine · doi:10.1097/psy.0000000000001053 · Cited by 24
Deslée, G., Fabry-Vendrand, C., Poccardi, N., Thabut, G., Pitsaer, C. E., Coriat, A., Renaudat, C., Maguire, A., & Pinto, T. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001585 · Cited by 26
Use Patterns of Long-acting Bronchodilators in Routine COPD Care: The OUTPUL Study
Martino, M. D., Agabiti, N., Bauleo, L., Kirchmayer, U., Cascini, S., Pistelli, R., Colamesta, V., Patorno, E., Pinnarelli, L., Fusco, D., et al. (2013) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2013.839646 · Cited by 26
Rio, F. G., Soler‐Cataluña, J. J., Navarrete, B. A., Viejo, J. L., & Miravitlles, M. (2017) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2017.1365120 · Cited by 26
“Moreover, and despite evidence that adherence is strongly associated with a reduced risk of death and fewer hospital admissions (10), poor adherence to inhaled medication is common among patients with COPD (11), and it has been reported that an average of 60% of patients with COPD do”
BackgroundChang, T.-Y., Chien, J., Wu, C., Dong, Y., & Lin, F. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.12.006 · Cited by 26
Baldwin, D. S., Necking, O., Schmidt, S. N., Ren, H., & Reines, E. H. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.098 · Cited by 25
Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm
Wilkie, M., Finch, S., & Schembri, S. (2015) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2014.995288 · Cited by 26
Differences in Adherence to Common Inhaled Medications in COPD
Huurne, K. K.-T., Movig, K. L. L., van der Valk, P., van der Palen, J. A. M., & Brusse-Keizer, M. G. J. (2015) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2014.995292 · Cited by 25
“After obtaining the patient can underuse, overuse or show improper use (for example forgetfulness and alteration of schedules and doses) of the medication (4,8).”
Høeg, E. R., Bruun‐Pedersen, J. R., & Serafin, S. (2021) · IEEE Conference on Virtual Reality and 3D User Interfaces Abstracts and Workshops (VRW) · doi:10.1109/vrw52623.2021.00052 · Cited by 26
“due to a greater amount of comorbidities and cognitive deficits [6].”
BackgroundInfluentialPorter, V., Halpern, R., Baker, B. I., Su, Woodruff, Paulose-Ram, & Shah (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s19991 · Cited by 25
“26 in the fluticasone/salmeterol cohort – align with adherence estimates of 10%–40% in clinical practice documented by Bourbeau and Bartlett.(14) Low adherence to inhaled medications is not unique to COPD; it has also been documented among individuals using inhaled therapies for treatment of asthma.”
InfluentialFerguson, G. T., Ghafouri, Dai, & Dunn (2013) · International Journal of COPD · doi:10.2147/copd.s38577 · Cited by 25
Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey
Braido, F., Baiardini, I., Sumberesi, M., Blasi, F., & Canonica, G. W. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-94 · Cited by 25
“One of the main problems is a lack of adherence to treatment by patients [12-17].”
BackgroundHollingworth, K., Müllerová, H., Landis, S., Айсанов, З. Р., Davis, K. J., Ichinose, M., Mannino, D. M., Maskell, J., Menezes, A. M. B., van der Molen, T., et al. (2016) · International Journal of COPD · doi:10.2147/copd.s102280 · Cited by 26
“an association between increased number of comorbidities and poorer adherence.(11) This is an important point for treat-”
BackgroundResultHesso, I., Nabhani‐Gebara, S., Greene, G., stello, R. W. C., & Kayyali, R. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13437 · Cited by 24
Moradkhani, B., Mollazadeh, S., Niloofar, P., Bashiri, A., & Oghazian, M. B. (2021) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-021-00222-x · Cited by 28
“high health status, they take their medication more willingly [37, 40].”
BackgroundWei, Y. J., Simoni‐Wastila, L., Albrecht, J. S., HUANG, T.-Y. J., Moyo, P., Khokhar, B., Harris, I., LANGENBERG, P. W., Netzer, G., & Lehmann, S. W. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4772 · Cited by 26
“Underlying reasons for suboptimal medication treatment of COPD are complex and include patient‐related (eg, patients0 perception of the disease), treatment‐related (eg, complex regimens), and social/environmental (eg, patient‐prescriber relationship) factors.(12) Understanding optimal clinical management of multimorbi…”
BackgroundRicheldi, L., Schino, P., Bargagli, E., Rícci, A., Rocca, A., Marchesani, F., Pennisi, A., Camiciottoli, G., D’Amato, M., Macagno, F., et al. (2024) · International Journal of COPD · doi:10.2147/copd.s445858 · Cited by 23
“29,30 The fixed combination and the use of a single inhaler seem beneficial in increasing long-term adherence and could improve symptom control, reduce the exacerbation risk, and even potentially decrease healthcare costs.”
BackgroundLong-acting ß-adrenoceptor agonists in the management of COPD: focus on indacaterol
Beeh, K. M. (2011) · International Journal of COPD · doi:10.2147/copd.s7371 · Cited by 23
Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
Chung, V. C., Ma, H., Hui, D. S. C., Tam, W., & Tang, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070784 · Cited by 23
“Clinicians may prefer indacaterol as the b2 agonist bronchodilator of choice, as once daily administration may enhance patient adherence, [29] and subsequently reduce risk of death and hospitalization [30].”
BackgroundEnlightening chronic obstructive pulmonary disease through patients’ and caregivers’ narratives
Gatti, V., Banfi, P. I., Centanni, S., D'Antonio, S., Giustini, S. E., Piraino, A., Zibellini, M., & Marini, M. G. (2018) · International Journal of COPD · doi:10.2147/copd.s172214 · Cited by 23
Cappuccio, A., Sanduzzi, A., Verga, M., Nardini, S. G., Policreti, A., Porpiglia, P. A., Napolitano, S., & Marini, M. G. (2018) · ERJ Open Research · doi:10.1183/23120541.00155-2017 · Cited by 26
Efficacy of indacaterol in the treatment of patients with COPD
Jones, P., Barnes, N. C., Vogelmeier, C. F., Lawrence, D., & Krämer, B. (2011) · Primary Care Respiratory Journal · doi:10.4104/pcrj.2011.00066 · Cited by 22
“A fast onset may be beneficial in giving patients confidence that they have taken their medication correctly, and may help their adherence to treatment.(18) b) Breathlessness Breathing difficulties are the most common reason for COPD patients to seek medical attention.”
BackgroundInhalation device options for the management of chronic obstructive pulmonary disease
DePietro, M. R., Gilbert, I., Millette, L. A., & Riebe, M. T. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1399042 · Cited by 22
“A growing interest in this approach could prompt HCPs to tailor disease management programs to patient preference to promote adherence [100].”
Backgroundde Moreira, A. T. A., Pinto, C. R., Lemos, A. C. M., Costa, L. A., Souza, G. S., & Netto, E. M. (2022) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210120 · Cited by 22
“0%.(5-9) In fact, the causes associated with the lack of adherence are being more commonly reported as level of schooling, pulmonary function, severity of disease and the presence of symptoms.”
BackgroundQuality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
Kort, S., Huurne, K. K.-T., van der Palen, J. A. M., van Beurden, W., Movig, K. L. L., van der Valk, P., & Brusse-Keizer, M. G. J. (2016) · International Journal of COPD · doi:10.2147/copd.s107303 · Cited by 23
Fischer, W., Brandstetter, S., Brandl, M., Finger, T., Böhmer, M. M., Pfeifer, M. A., & Apfelbacher, C. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2018.02.004 · Cited by 22
“Adherence levels in patients with chronic pulmonary diseases are low (Bourbeau and Bartlett, 2008; Sumino and Cabana, 2013).”
BackgroundWitry, M. J., Comellas, A. P., Simmering, J. E., & Polgreen, P. M. (2018) · Journal of Medical Internet Research · doi:10.2196/jmir.9382 · Cited by 22
“Barriers to COPD therapy adherence include the complexity and cost of regimens, incorrect medication knowledge and beliefs, health literacy, and cognitive deficits [4,7,8].”
Chen, J. W., Kaye, L., Tuffli, M., Barrett, M., Jones-Ford, S., Shenouda, T., Gondalia, R., Henderson, K., Combs, V., Sickle, D. V., et al. (2019) · JMIR Formative Research · doi:10.2196/13286 · Cited by 22
“Historically, information on patient use of SABA has been self-reported, leading to challenges of recall bias through incorrect recollection or fabrication [7-9].”
BackgroundTai Chi as a form of exercise training in people with chronic obstructive pulmonary disease
Leung, R. W., McKeough, Z. J., & Alison, J. A. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2013.839244 · Cited by 24
Cope, S. F., Zhang, J., Williams, J., & Jansen, J. P. (2012) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-12-29 · Cited by 21
“Compared to the twice daily dosing required for salmeterol and formoterol, the once daily regimen for indacaterol may improve adherence in clinical practice [42], which has been reported to range from rates as low as 10% to 40% for COPD medication [42–45].”
BackgroundShrestha, R., Pant, A., Shrestha, S., Shrestha, B., Gurung, R., & Karmacharya, B. (2015) · Kathmandu University Medical Journal · doi:10.3126/kumj.v13i1.13756 · Cited by 21
Switching Inhalers: A Practical Approach to Keep on UR RADAR
Kaplan, A. G., & van Boven, J. F. M. (2020) · Pulmonary Therapy · doi:10.1007/s41030-020-00133-6 · Cited by 21
Kaye, L., Gondalia, R., Thompson, A., Stempel, D. A., & Barrett, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-03827-2 · Cited by 21
Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD
Donner, C. F., Amaducci, S., Bacci, E., Baldacci, S., Bartoli, M. L., Beghi, G. M., Benfante, A., Brighindi, S., Casali, L., Castiglia, D., et al. (2018) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2018.886 · Cited by 21
“…diseases, non-adherence in patients with chronic respiratory diseases is common and contributes to adverse health outcomes, reduced quality of life, increased morbidity, increased health care expenditures, unnecessary escalation in therapies and even hospitalizations and mortality [180-183].”
Vytrisalova, M., Hendrychova, T., Touskova, T. P., Zimčíková, E., Vlček, J., Nevoránek, L., Svoboda, M., Hejduk, K., Brat, K., Plutinský, M., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00241 · Cited by 21
“In addition, it has been reported that A-ApplT in COPD patients varies depending on a clinician’s speciality and their experience (Bourbeau and Bartlett, 2008; Restrepo et al., 2008).”
BackgroundQualidade de vida e bem-estar espiritual em pacientes com doença pulmonar obstrutiva crônica
da Silva, M. S., Kimura, M., Stelmach, R., & Santos, V. L. C. D. G. (2009) · Revista da Escola de Enfermagem da USP · doi:10.1590/s0080-62342009000600007 · Cited by 21
Metadata
- Authors
- Bourbeau, J., & Bartlett, S. J.
- Affiliations
- McGill University Health Centre (CA)
- Johns Hopkins University (US)
- Corresponding author
- Bourbeau, J
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2008-09-01
- Volume
- 63
- Issue
- 9
- Pages
- 831-838
- ISSN
- 0040-6376 (ISSN-L)
- PMC
- PMC4747423
- OpenAlex
- W2138833643
- Cited by
- 490
- References
- 101
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 25 · 2023: 22 · 2022: 24 · 2021: 32 · 2020: 30 · 2019: 24 · 2018: 42 · 2017: 34 · 2016: 37 · 2015: 23 · 2014: 37 · 2013: 41 · 2012: 24
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Thorax (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- McGill University
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR051351)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Health Professions › Pharmacy › Pharmacy and Medical Practices
- Keywords
- chronic obstructive pulmonary disease, medication adherence, patient-provider communication, self-management, polypharmacy, complex medication regimens, smoking, health care utilization, quality of life
- MeSH terms
- Attitude to Health, Communication, Humans, Patient Compliance, Perception, Professional-Patient Relations, Caregivers, Polypharmacy, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
